Literature DB >> 28367880

Predation Efficacy of Bdellovibrio bacteriovorus on Multidrug-Resistant Clinical Pathogens and Their Corresponding Biofilms.

Yao Sun1, Jianzhong Ye2,3, Yuanbo Hou4, Huale Chen1, Jianming Cao4, Tieli Zhou1.   

Abstract

The aim of the present study was to evaluate the predation efficacy of Bdellovibrio bacteriovorus on multidrug-resistant (MDR) or extensive drug resistant (XDR) gram-negative pathogens and their corresponding biofilms. In this study, we examined the ability of B. bacteriovorus to prey on MDR and XDR gram-negative clinical bacteria, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Results showed that B. bacteriovorus was able to prey on all planktonic cultures, among which the most efficient predation was observed for drug-resistant E. coli, with a 3.11 log10 reduction in viability. Furthermore, B. bacteriovorus demonstrated promising efficacy in preventing biofilm formation and dispersing the established biofilm. Reductions in biofilm formation of E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii co-cultured with B. bacteriovorus were 65.2%, 37.1%, 44.7%, and 36.8%, respectively. Meanwhile, the established biofilms of E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii were significantly reduced by 83.4%, 81.8%, 83.1%, and 79.9%, respectively. A visual analysis supported by scanning electron microscopy demonstrated the role of B. bacteriovorus in removing the established biofilms. This study highlights the potential use of B. bacteriovorus as a biological control agent with the capability to prey on MDR/XDR gram-negative pathogens and eradicate biofilms.

Entities:  

Keywords:  Bdellovibrio bacteriovorus; antimicrobials; biofilms; resistance

Mesh:

Year:  2017        PMID: 28367880     DOI: 10.7883/yoken.JJID.2016.405

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  7 in total

1.  Susceptibility of colistin-resistant pathogens to predatory bacteria.

Authors:  Sonal Dharani; Dong Hyun Kim; Robert M Q Shanks; Yohei Doi; Daniel E Kadouri
Journal:  Res Microbiol       Date:  2017-09-15       Impact factor: 3.992

2.  Characterization of the first highly predatory Bdellovibrio bacteriovorus from Iran and its potential lytic activity against principal pathogenic Enterobacteriaceae.

Authors:  Salman Odooli; Rasoul Roghanian; Giti Emtiazi; Milad Mohkam; Younes Ghasemi
Journal:  Iran J Basic Med Sci       Date:  2020-10       Impact factor: 2.699

Review 3.  Biotechnological Potential of Bdellovibrio and Like Organisms and Their Secreted Enzymes.

Authors:  Eleni Bratanis; Tilde Andersson; Rolf Lood; Ewa Bukowska-Faniband
Journal:  Front Microbiol       Date:  2020-04-15       Impact factor: 5.640

Review 4.  Microbiome Modulation as a Novel Strategy to Treat and Prevent Respiratory Infections.

Authors:  Barbara C Mindt; Antonio DiGiandomenico
Journal:  Antibiotics (Basel)       Date:  2022-04-01

Review 5.  Potential probiotic approaches to control Legionella in engineered aquatic ecosystems.

Authors:  Alessio Cavallaro; William J Rhoads; Simona G Huwiler; Elyse Stachler; Frederik Hammes
Journal:  FEMS Microbiol Ecol       Date:  2022-07-28       Impact factor: 4.519

6.  Dual Predation by Bacteriophage and Bdellovibrio bacteriovorus Can Eradicate Escherichia coli Prey in Situations where Single Predation Cannot.

Authors:  Laura Hobley; J Kimberley Summers; Rob Till; David S Milner; Robert J Atterbury; Amy Stroud; Michael J Capeness; Stephanie Gray; Andreas Leidenroth; Carey Lambert; Ian Connerton; Jamie Twycross; Michelle Baker; Jess Tyson; Jan-Ulrich Kreft; R Elizabeth Sockett
Journal:  J Bacteriol       Date:  2020-02-25       Impact factor: 3.490

Review 7.  Insight into the Possible Use of the Predator Bdellovibrio bacteriovorus as a Probiotic.

Authors:  Giulia Bonfiglio; Bruna Neroni; Giulia Radocchia; Massimiliano Marazzato; Fabrizio Pantanella; Serena Schippa
Journal:  Nutrients       Date:  2020-07-28       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.